Medifast (NYSE:MED - Get Free Report) updated its first quarter 2025 earnings guidance on Tuesday. The company provided EPS guidance of -0.500-0.000 for the period, compared to the consensus EPS estimate of -0.190. The company issued revenue guidance of $100.0 million-$120.0 million, compared to the consensus revenue estimate of $130.8 million.
Analysts Set New Price Targets
Separately, DA Davidson dropped their target price on Medifast from $17.00 to $16.50 and set a "neutral" rating for the company in a report on Wednesday.
Get Our Latest Research Report on Medifast
Medifast Price Performance
MED stock traded up $0.38 during midday trading on Friday, reaching $14.71. The company had a trading volume of 329,782 shares, compared to its average volume of 232,291. The company has a market capitalization of $160.96 million, a price-to-earnings ratio of 81.74 and a beta of 1.14. The stock has a 50 day moving average price of $16.25 and a 200-day moving average price of $17.97. Medifast has a 1-year low of $13.57 and a 1-year high of $42.68.
Medifast (NYSE:MED - Get Free Report) last posted its quarterly earnings results on Tuesday, February 18th. The specialty retailer reported $0.10 EPS for the quarter, beating analysts' consensus estimates of ($0.16) by $0.26. The business had revenue of $119.00 million during the quarter, compared to the consensus estimate of $114.25 million. Medifast had a return on equity of 10.64% and a net margin of 0.35%. As a group, research analysts anticipate that Medifast will post 0.51 earnings per share for the current year.
Medifast Company Profile
(
Get Free Report)
Medifast, Inc, through its subsidiaries, engages in the manufacture and sale of weight loss, weight management, and healthy living products in the United States and the Asia-Pacific. It offers bars, puffs, cereal, crunchers, drinks, hearty choices, oatmeal, pancakes, pudding, soft serve, shakes, smoothies, soft bakes, and soups under the OPTAVIA, OPTAVIA ACTIVE, and Optimal Health brand names.
Further Reading
Before you consider Medifast, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Medifast wasn't on the list.
While Medifast currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
